Pretomanid: XDR-TB may soon become easily treatable
Though the total number of people with XDR-TB and treatment intolerant or non-responsive MDR-TB who will require the new anti-TB drug Pretomanid may not be high, these are people who…
Category: TB Alliance
Explainer: What makes the new drug-resistant TB medicine Pretomanid promising
When used in combination with bedaquiline and linezolid, the newly approved pretomanid drug for MDR-TB and XDR-TB had an overall treatment success rate of about 90%. Besides better effectiveness, the…
‘Child-friendly paediatric TB drugs will be a game changer’
Treating young children afflicted with drug-sensitive TB disease will no longer be the same. After years of neglect, the availability of flavoured, easily dissolvable first-line TB drugs in correct doses…
Child-friendly TB drugs launched
For the first time, child-friendly TB drugs for first-line medication in a fixed-dose combination was launched by TB Alliance, UNITAID and WHO at the 46th Union World Conference on Lung…
PaMZ drug combination is a game changer for TB and MDR-TB treatment
A novel drug combination (PaMZ) designed to treat both drug-sensitive and MDR-TB, including those who are HIV positive, is advancing to the crucial Phase III human clinical trial. If all…
Child-friendly, first-line TB combination drugs will be available in 2016: Dr. Mel Spigelman
Dr. Mel Spigelman, President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance) is regarded as one of the world’s leading experts in tuberculosis and…
